Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics, Inc.'s stock price declined by 36.63% between October 23, 2024, and October 22, 2025. In October 2024, Inhibikase announced the closing of a private placement financing of approximately $110 million, with potential aggregate financing of up to $275 million upon the full cash exercise of warrants. In the second quarter of 2025, the company continued to advance IKT-001 towards a late-stage clinical trial in PAH and finalized the study protocol for the IMPROVE-PAH Phase 2b study, expected to initiate in the second half of 2025. Inhibikase Therapeutics also announced its first and second-quarter 2025 financial results in May and August 2025, respectively, and appointed a Chief Commercial and Strategy Officer in August 2025 and a Chief Financial Officer in April 2025. The decision to halt further development of risvodetinib (IkT-148009) following results from the Phase 2 '201 trial', which reported 49 adverse events, raised concerns about the drug's safety profile and led to a downgrade in the stock rating.

Information regarding the demand seasonality for Inhibikase Therapeutics, Inc.'s products and services is not publicly available in the provided search results.

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small molecule therapeutics for challenging diseases within the neurodegenerative, cardiopulmonary, and oncology areas. The company's major product candidates include IkT-148009 (Risvodetinib), a small molecule Abelson tyrosine kinase inhibitor in Phase 2a clinical trials for Parkinson's disease and related disorders, and IkT-001Pro, a prodrug of imatinib mesylate in preclinical development for blood and stomach cancers and advancing into a late-stage clinical trial for Pulmonary Arterial Hypertension (PAH).

Inhibikase Therapeutics, Inc. is headquartered in Atlanta, Georgia, and maintains offices in Lexington, Massachusetts. The company has research and development collaborations with institutions such as Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University.

Inhibikase Therapeutics' reputation has been affected by the decision to halt the further development of risvodetinib (IkT-148009) for Parkinson's disease due to safety concerns arising from adverse events in its Phase 2 '201 trial', leading to a downgrade in the company's stock rating. Despite this, the company currently holds a "Moderate Buy" consensus rating from Wall Street analysts.

Inhibikase Therapeutics, Inc. is primarily owned by institutional shareholders, who hold approximately 73.15% of the company's stock, while insiders own about 27.13%, and retail investors hold 0.00%. Another source indicates institutional investors hold around 60.31% of the stock, insiders 9.88%, and public companies and individual investors 19.17%. Major institutional owners include Sands Capital Alternatives LLC, Soleus Capital Management, L.P., Fairmount Funds Management LLC, Perceptive Advisors Llc, Commodore Capital Lp, ADAR1 Capital Management, LLC, Vanguard Group Inc, BlackRock, Inc., Blackstone Group Inc, and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. Sands Capital Life Sciences Pulse Fund II LP is noted as the largest individual shareholder, owning 10.95 million shares, representing 14.69% of the company.